Advicenne announces the launch of a capital increase through the issue of new ordinary shares (the New Shares) with shareholders' pre-emptive subscription rights (the DPS), for an initial amount of 6.0 ME, which may be increased to 6.9 ME if the extension clause is exercised in full.

The Capital Increase will be carried out through the issue of 2,489,287 New Shares at a unit price of E2.41, representing a 27.4% discount to Advicenne's closing share price on September 8, 2023 (E3.32), which may be increased to 2,862,680
New Shares if the Extension Clause is exercised.

The funds will be allocated as follows:
- around 40% to the commercial development of Sibnayal®, particularly in France and the United Kingdom where Advicenne markets it directly;
- around 40% to optimizing the industrial and clinical development of ADV7103;
- finally, 20% to finance the Company's ongoing operations.

This Capital Increase will ensure the financing of Advicenne's anticipated cash requirements until at least mid-2025 if the Capital Increase is carried out at 100%, and at least until the first quarter of 2025 if it is carried out at 75%.

Copyright (c) 2023 CercleFinance.com. All rights reserved.